Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel backs Xenazine

FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 12-0 on Thursday to recommend approval of Xenazine

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE